ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors

Core Insights - Oryzon Genomics has received a Decision to Grant from the European Patent Office for its patent application EP20712594.9, which covers the use of iadademstat in combination with PD1 or PD-L1 inhibitors for cancer therapy, including small cell lung cancer (SCLC) [1][2] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [5] - The company has a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [5] - Oryzon's team consists of experienced professionals from the pharmaceutical industry, with locations in Barcelona, Boston, and San Diego [5] Product Development - Iadademstat is a selective inhibitor of the epigenetic enzyme LSD1, currently being investigated in various clinical trials for hematologic cancers and solid tumors [6] - The drug is being tested in combination with PD-L1 inhibitors in a Phase I/II trial for extensive-disease SCLC patients, sponsored by the U.S. National Cancer Institute [4][6] - Iadademstat has shown promising safety and efficacy in trials for acute myeloid leukemia (AML) and is being evaluated for other indications, including sickle cell disease and essential thrombocythemia [6] Patent and Market Position - The granted patent for iadademstat will remain in force until at least 2040, with corresponding patents already allowed in Australia and Russia, and applications pending in the U.S., Japan, and China [2][3] - The patent strengthens Oryzon's position in the market for cancer therapies that utilize immune checkpoint inhibitors [3]